U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Cover of Drugs and Lactation Database (LactMed®)

Drugs and Lactation Database (LactMed®) [Internet].

Show details

Sodium Polystyrene Sulfonate

Last Revision: July 19, 2021.

Estimated reading time: 1 minute

CASRN: 9080-79-9

image 135039523 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

Because sodium polystyrene sulfonate is not orally absorbed, it is unlikely to reach the breastmilk or adversely affect the breastfed infant after maternal administration. No special precautions are required.

A suspension of sodium polystyrene sulfonate has been added directly to breastmilk to lower the potassium concentration of milk for use in infants with renal impairment. In addition to lowering average potassium content by 65%, the calcium content of breastmilk was reduced by 84%.[1] Infants given either expressed breastmilk, formula or a combination of both had their average serum potassium levels decreased by 24% from 6.3 to 4.8 mEq/L. Serum calcium and creatinine also decreased slightly. The infants had no clinically noticeable side effects.[2] Addition of large amounts of sodium polystyrene sulfonate to artificial formula also lowers the calcium, copper, manganese, phosphorus, sulfur and zinc concentrations; whereas the iron, sodium and sulfur content of formulas are increased.[3] Similar changes might occur with breastmilk.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider



Bonnet L, Goudable J, Accominotti M, et al. Nephrologie. 1997;18:287–9. [Effect of polystyrene sulfonate resins on milk ionic concentration] [PubMed: 9496569]
Thompson K, Flynn J, Okamura D, et al. Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(R)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency. J Ren Nutr. 2013;23:333–9. [PubMed: 23707305]
Taylor JM, Oladitan L, Carlson S, et al. Renal formulas pretreated with medications alters the nutrient profile. Pediatr Nephrol. 2015;30:1815–23. [PMC free article: PMC4572699] [PubMed: 25930981]

Substance Identification

Substance Name

Sodium Polystyrene Sulfonate

CAS Registry Number


Drug Class

Breast Feeding


Cation Exchange Resins

Chelating Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500750PMID: 29999809


Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...